Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, ...

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...

Aromatase inhibitors act through pure oestrogen deprivation to achieve an endocrine response in oestrogen receptor (ER)-positive breast cancer. Both experimental and clinical data now confirm that ...

Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

A number of adjuvant breast cancer trials are currently evaluating all 3 third-generation aromatase inhibitors relative to the current standard, tamoxifen for 5 years. In comparing efficacy and ...

I have been on an aromatase inhibitor for the past eight months and have side effects that keep me from having a good quality of life. I am supposed to be on it for five years, but I do not want ...

Today’s standard first-line care combines an aromatase inhibitor with one of three CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib). These drugs slow cancer growth by putting the cell ...

Panelists discuss the SERENA-6 trial evaluating camizestrant, which uniquely enrolled patients with molecularly detected ESR1 ...

I have been on an aromatase inhibitor for the past eight months and have side effects that keep me from having a good quality of life. I am supposed to be on it for five years, but I do not want ...

Aromatase inhibitors work to lower your levels of estrogen. These oral meds are usually taken once a day. They include the drugs letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin).

TUESDAY, Sept. 17, 2024 (HealthDay News) -- For postoperative patients with breast cancer, the duration of aromatase inhibitor (AI) treatment is not associated with the risk for coronary artery ...